Loading clinical trials...
Loading clinical trials...
A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice
Conditions
Interventions
Tirzepatide
Locations
43
United States
Medical Dermatology Specialists
Phoenix, Arizona, United States
First OC Dermatology Research Inc
Fountain Valley, California, United States
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States
Metropolis Dermatology
Los Angeles, California, United States
Northridge Clinical Trials
Northridge, California, United States
Alliance for Multispecialty Research, LLC
Fort Myers, Florida, United States
Start Date
March 19, 2025
Primary Completion Date
May 1, 2028
Completion Date
May 1, 2028
Last Updated
April 17, 2026
NCT06979453
NCT07449234
NCT07116967
NCT07250802
NCT07449702
NCT07290569
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions